CAR/TCR-T, NK, Treg, iPSC, in-vivo gene therapy, viral vectors — manufactured in seven Grade B suites at Alameda, with the platform flexibility to match your process to the science, not the other way around.
We're built for the cell & gene therapy field's full breadth — autologous, allogeneic, ex-vivo, and in-vivo. One integrated platform, multiple expansion technologies, all in seven suites at Alameda.
Autologous and allogeneic CAR-T and TCR-T workflows — lentivirus or gamma-retrovirus transduction, expansion in G-Rex or WAVE, fill in bags or vials.
Feeder-expanded or feeder-free NK cell programs with optimized cryopreservation — retaining post-thaw viability and in-vivo function.
Regulatory T-cell therapies with closed-system expansion and validated suppression assays.
Beyond ex-vivo: directly engineered viral vectors and cell-specific promoters for next-generation in-vivo therapies — built backwards from the clinical indication.
Pluripotent and aggregate cell programs on PBS Vertical Wheel — same hydrodynamics from 0.1 L mini to 80 L production.
Lentivirus & gamma-retrovirus — adherent (2–20 L) and suspension (1.5–200 L GMP). Multiple envelope pseudotype options, stable producer line engineering.
Our platforms are tunable. ASCs, MSCs, hepatocyte and tissue-derived products (e.g. Lygenesis-style organ regeneration), and other adherent or suspension cell types — we adapt the process to your science, not the other way around.
The full set of capabilities that make up our integrated CDMO platform.
SynBio research, ML-driven optimization, proprietary tools for next-gen therapies.
Adherent & suspension lentivirus — 2 L to 200 L GMP. Targeting and control built in.
Engineering, Master, and Working cell bank generation. Adherent & suspension.
Knowledge transfer as a discipline. Development-to-GMP in ~7 months.
Dedicated PMO, transparent Gantts, real-time data exchange. One accountable team.
